Press Releases

ENDO Trial Placed on Enrollment Hold

LEXINGTON, Mass & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced today that the U.S. Food and Drug Administration (FDA) has placed a hold on...

read more

Appendix 4C Quarterly Report Quarter ended 31 December 2014

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 January 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the quarter ended...

read more

GI Dynamics, Inc. Announces Corporate Restructuring and Departure of Chief Financial Officer

LEXINGTON, Massachusetts & SYDNEY, Australia – 8 December 2014 – GI Dynamics, Inc. (ASX: GID) a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that the Company and Robert W. Crane, its chief financial officer, secretary and treasurer,...

read more

GI Dynamics, Inc. Announces Corporate Restructuring and Departure of Chief Financial Officer

LEXINGTON, Massachusetts & SYDNEY, Australia – 8 December 2014 – GI Dynamics, Inc. (ASX: GID) a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that the Company and Robert W. Crane, its chief financial officer, secretary and treasurer,...

read more

GI Dynamics Resumes Shipments of EndoBarrier® Product

Notified Body, following review, clears Company to resume shipments LEXINGTON, Massachusetts – 1 December 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an...

read more

GI Dynamics to Present at the 26th Annual Piper Jaffray Healthcare Conference

LEXINGTON, Massachusetts & SYDNEY, Australia – 19 November 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that Michael Dale, president and chief executive officer, is scheduled to present at the...

read more

Appendix 4C Quarterly Report Quarter ended 30 September 2014

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Third Quarter 2014 on Tuesday, 4 November 2014 at 5 p.m. U.S. EST / Wednesday, 5 November 2014 at 9 a.m. AEDT LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 31 October 2014 – GI Dynamics, Inc. (ASX: GID) (GI...

read more

Special Meeting of Stockholders – Access for Participants by Webcast and Conference Call

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 October 2014 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company) will hold its Special Meeting of Stockholders on Monday, November 10, 2014, at 5:00 p.m., United States Eastern Standard Time (which is 9:00 a.m. on Tuesday,...

read more

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Third Quarter 2014

LEXINGTON, Massachusetts & SYDNEY, Australia – 28 October 2014 – GI Dynamics, Inc. (ASX: GID) will hold a conference call to discuss the company’s financial results for the third quarter and six months ended 30 September 2014, and its business outlook. Michael D. Dale, president and chief...

read more

Application for Listing on NASDAQ Capital Market

Lexington, Massachusetts, United States and Sydney, Australia – 28 October 2014 – GI Dynamics, Inc. (ASX: GID) (“GI Dynamics” or the “Company”), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced today that it has filed an application to list its...

read more
Page 4 of 10« First...23456...10...Last »